Form 4 for PYXS Pyxis Oncology, Inc.
Accepted 2023-09-25 00:00:00 ET · period of report 2023-09-25 · accession 0001209191-23-050492 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-25 | 2023-09-25 | PYXS | Connealy Pamela Ann | CFO, COO | P - Purchase | $1.67 | +12.0K | 804.1K | +2% | +$20.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-25 | P | A | 12,000 | $1.67 | 804,106 | D | — | — | (F1) Represents the weighted average purchase price of common stock purchased by the Reporting Person in open market transactions. The range of purchase prices on the transaction date was $1.615 to $1.70 per share. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each price. |